Status:
ACTIVE_NOT_RECRUITING
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
Radboud University Medical Center
Conditions:
Prostatic Neoplasms
Genital Neoplasms, Male
Eligibility:
MALE
Brief Summary
The purpose of the study is to combine and correlate data from morphological and functional MRI, molecular signatures of tumor hypoxia, the presence of micrometastases and tumor hypoxia with the goal ...
Detailed Description
A prospective study including 180 consecutive patients with PCa referred to Oslo University Hospital, Radiumhospitalet, for surgical treatment. In vivo functional MRI examination will be performed wit...
Eligibility Criteria
Inclusion
- Patients suitable for surgery with confirmed prostate cancer, Gleason grade ≥ 3
- Patient has received no prior treatment for prostate cancer.
- Patient has adequate renal function: Estimated creatinine clearance ≥ 60 ml/minute.
- Patient must sign written informed consent according to the protocol approved by the Regional Ethics Committee.
Exclusion
- Patient with contraindication to MR or MR contrast media according to clinical practice.
- Patients who want to withdraw for any reason during the study.
- Patients previously undergone pelvic surgery or radiation therapy
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2030
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01464216
Start Date
October 1 2011
End Date
December 1 2030
Last Update
June 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital
Oslo, Norway, 0310